A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(85 sites)

United States

Site Number - 1010, Anniston, Alabama

Site Number - 1020, Birmingham, Alabama

Site Number - 1038, Phoenix, Arizona

Site Number - 1034, Scottsdale, Arizona

Site Number - 1022, Beverly Hills, California